Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics has notified Pfizer of its decision to defer a milestone payment related to ORLYNVAH for two years, until October 25, 2026, as per an SEC filing.
November 01, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iterum Therapeutics has chosen to defer a milestone payment to Pfizer for ORLYNVAH until 2026, which may impact its financial obligations and cash flow management.
Deferring the milestone payment allows Iterum Therapeutics to manage its cash flow better in the short term, potentially reducing financial pressure and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Pfizer has been notified by Iterum Therapeutics about the deferral of a milestone payment for ORLYNVAH until 2026, which may have a minor impact on its expected cash inflows.
The deferral of the milestone payment by Iterum Therapeutics may slightly affect Pfizer's short-term cash inflows, but given Pfizer's size, the impact is likely minimal.
CONFIDENCE 85
IMPORTANCE 30
RELEVANCE 60